lostened Menstruation Problems: PCOS, Dysmenorrhea & Endometriosis Study Guide

Dysmenorrhea: Overview and Management

  • Definition: Painful cramping associated with menstruation.     - Primary Dysmenorrhea: Pain without underlying uterine pathology.     - Secondary Dysmenorrhea: Pain associated with underlying uterine pathology, such as uterine polyps or endometriosis.

  • Prevalence and Impact:     - Extremely common in adolescents, affecting up to 93%93\% of this population.     - Approximately 15%15\% of individuals experience severe, disabling dysmenorrhea.

  • Treatment Approaches:     - Non-pharmacological: Includes exercise, yoga, topical heat application, and Transcutaneous Electrical Nerve Stimulation (TENS).     - Pharmacological First-Line Options:         - NSAIDs: Example: Ibuprofen 400 mg400\,mg TID (taken three times daily).             - Dosing Strategy: Start at the onset of pain and continue with around-the-clock dosing for the first 2−32-3 days of the menstrual cycle.         - Hormonal Contraceptives: Used as a primary medical therapy to manage symptoms.

Polycystic Ovarian Syndrome (PCOS): Diagnosis and Pathophysiology

  • Diagnostic Criteria: Diagnosis requires the presence of at least two of the following three criteria:     - Androgen Excess: Clinical (e.g., hirsutism) or biochemical (elevated serum levels).     - Ovulatory Dysfunction: Typically manifest as irregular cycles.     - Polycystic Ovaries: Identified via imaging.

  • Diagnostic Challenges: Diagnosis is notably difficult during adolescence and the peri- and post-menopausal life stages.

  • Pathophysiology and Underlying Causes:     - Insulin Resistance: Characterized by clinical signs and complications including:         - Central fat distribution.         - Impaired glucose tolerance and Type 2 diabetes.         - Acanthosis Nigricans: Skin hyperpigmentation often found in body folds.     - Excess Androgen Production: Leading to:         - Hirsutism: Excess body hair.         - Acne.         - Male-pattern alopecia: Hair thinning/loss.

  • Clinical Symptoms:     - Menstrual abnormalities.     - Hirsutism and acne.     - Infertility.

Long-Term Health Risks Associated with PCOS

  • Individuals with PCOS face significantly increased risks for various conditions:     - Metabolic: Impaired glucose tolerance, Gestational diabetes, and Type 2 diabetes.     - Cardiovascular: Hyperlipidemia, hypertension, and coronary heart disease.     - Respiratory: Obstructive sleep apnea.     - Oncological: Endometrial cancer.     - Psychological: Depression, anxiety, and eating disorders.     - Quality of Life: Body image issues and psychosexual dysfunction.

2023 International Guidelines for PCOS Management

  • The International Evidence-based Guideline for the assessment and management of polycystic ovary syndrome (2023) provides a comprehensive framework involving organizations like Monash University, ASRM, Endocrine Society, and ESHRE.

  • Key Areas of Recommendations:     - Screening and diagnostic assessment across the life-stage.     - Emotional wellbeing and risk assessment.     - Lifestyle interventions.     - Pharmacological treatment for non-fertility indications.     - Assessment and treatment of infertility.

Pharmacological Treatment of PCOS: Non-Fertility Indications

  • Combined Oral Contraceptive Pills (COCPs):     - Use in adults: Recommended for managing hirsutism and irregular cycles.     - Use in adolescents: Recommended to be "considered" for those diagnosed or "at-risk."     - Mechanism: Increases hepatic Sex Hormone-Binding Globulin (SHBG) production.     - Note on Formulations: Transdermal and vaginal formulations do not increase SHBG to the same extent and may be less effective for hyperandrogenism than oral CHCs.

  • COCP Prescribing Nuances:     - Various preparations show similar efficacy for hirsutism.     - There is no clinical advantage to using an ethinyl estradiol (EE) dose ≥30 μg\ge 30\,\mu g compared to doses < 30\,\mu g.     - Progesterone-only pills (POPs) may be considered specifically for endometrial protection.

  • Endometrial Cancer Prevention:     - To address hyperplasia from amenorrhea, a pragmatic approach suggests using COCPs in women with cycles lasting $> 90\,\text{days}$.     - The goal is to ensure a withdrawal bleed at least every 90 days90\,\text{days}, potentially using extended cycle COCPs.

  • Metformin:     - Indications: Consider in adults with PCOS and a $\text{BMI} \ge 25\,kg/m^2$ for improving insulin resistance, glucose, and lipid profiles.     - Adolescents: Consider for cycle regulation (limited evidence).     - Impact: Improves weight, BMI, Waist-to-Hip Ratio (WHR), testosterone, and cholesterol (specifically triglycerides).     - Considerations: Metformin is off-label for PCOS; monitor for GI side effects and B12B_{12} levels; requires proper dose titration.

  • Anti-obesity Medications: May be considered for obesity management in PCOS adults alongside active lifestyle interventions, following general population guidelines.

  • Anti-Androgens:     - Used for hirsutism if COCPs and cosmetic therapies provide suboptimal response after at least 6 months6\,\text{months}.     - Requirement: Must be used in combination with effective contraception due to teratogenic risks.     - Evaluation: Requires a 6−12 month6-12\,\text{month} course to evaluate efficacy.     - Common Agents and Dosing:         - Spironolactone: 25−100 mg25-100\,mg daily.         - Finasteride: 5−7.5 mg5-7.5\,mg daily.         - Flutamide: 250 mg250\,mg daily.

Comparative Analysis of Progestins in Combined Oral Contraceptives

Progestin Type

Generation/Derivative

Expected Androgenic Activity

Examples of Drugs

Common COC Products

Estranes

$1^{st}$ Gen (19-nortestosterone)

Androgenic activity

Norethindrone, Ethynodiol diacetate

Loestrin, Ortho-Novum, Zovia

Gonanes

$2^{nd}$ Gen (19-nor)

Androgenic activity

dl-Norgestrel, Levonorgestrel

Lo-Ovral, Alesse, Triphasil

Gonanes

$3^{rd}$ Gen (19-nor)

Diminished androgenic activity

Desogestrel, Gestodene, Norgestimate

Desogen, Ortho-Cept, Sprintec, Cyclessa

Spironolactone Deriv.

$4^{th}$ Gen

Antiandrogenic

Drospirenone

Yasmin, Yaz

  • Other Non-COC Products: Progesterone-only pills, NuvaRing, Nexplanon, Xulane.

Combination Therapies and Inositols in PCOS

  • COCP + Metformin:     - Offers little additional clinical benefit over monotherapy in adults with $\text{BMI} \le 30\,kg/m^2$.     - May be most beneficial for those with $\text{BMI} > 30\,kg/m^2$ or high metabolic risk factors.

  • COCP + Antiandrogens:     - Only considered for hirsutism after 6 months6\,\text{months} of COCP/cosmetic therapy failure.     - May be considered for androgen-related alopecia.

  • Inositols (Myo-inositol and D-chiro inositol):     - Description: Naturally occurring sugar alcohol found in cereals, meat, and citrus.     - Use: Can be considered based on patient preference; helps metabolic measures with limited impact on ovulation or weight.     - Clinical Data: Improves SHBG levels, ovulation rate, and reduces risk of Gestational Diabetes Mellitus (GDM).     - Dosing: Doses up to 4000 mg4000\,mg of myo-inositol daily are well-tolerated, though some reports of nausea, gas, or diarrhea exist.

Patient Case Study: PCOS Management Evolution

  • Initial Presentation (P.N., 27 y/o):     - Diagnosis: PCOS 3 years prior.     - Symptoms: Facial/back acne, hirsutism (upper lip).     - Status: Monogamous, using condoms, cycles 30−34 days30-34\,\text{days}.     - Vitals/Labs: $\text{BMI} = 25.9\,kg/m^2$, $\text{BP} = 119/62\,mmHg$, $\text{FBG} = 105\,mg/dL$, $\text{TSH} = 2.3\,mIU/L$.     - Recommendation: Initiate COCPs to address acne and hirsutism.

  • Follow-up (3 years later):     - Changes: Sedentary job, weight increase (BMI now 31 kg/m231\,kg/m^2).     - Vitals/Labs: $\text{BP} = 128/78\,mmHg$, $\text{FBG} = 120\,mg/dL$, $\text{A1C} = 6.1\%$.     - Recommendation: Discuss adding Metformin due to rising BMI and impaired fasting glucose/elevated A1C (high metabolic risk).

Endometriosis: Definition, Etiology, and Clinical Presentation

  • Definition: Presence of functional endometrial tissue located outside the uterine cavity.     - Common Sites: Ovaries, pelvic peritoneum, cervix, rectosigmoid colon, appendix, etc.     - Infertility: Present in up to 45%45\% of women with infertility.

  • Etiology: Complex; "Retrograde Menstruation" is a common theory where cells travel through fallopian tubes into the peritoneal cavity.

  • Clinical Presentation:     - Pelvic pain (cyclic or non-cyclic).     - Dysmenorrhea: Often starting 1−3 days1-3\,\text{days} before menses.     - Dyspareunia: Deep pain during or after sexual intercourse.     - Infertility.     - Cyclical GI and urinary symptoms.

  • Differential Diagnosis: Extensive, including Adenomyosis, Myoma, Interstitial cystitis, IBS, Pelvic Inflammatory Disease (PID), and Fibromyalgia.

Diagnosis and Staging of Endometriosis

  • ACOG Practice Guideline (2026):     - Clinical diagnosis is sufficient to start empiric treatment.     - Imaging: Transvaginal ultrasonography (initial); MRI for deep endometriosis.     - Laparoscopy: Considered the definitive method for staging and diagnosis.

  • Stages of Endometriosis:     1. Stage I (Minimal): Isolated lesions, no significant adhesions.     2. Stage II (Mild): Superficial lesions $< 5\,cm$ aggregate on peritoneum/ovaries; no significant adhesions.     3. Stage III (Moderate): Multiple implants (superficial and deep); peritubal/periovarian adhesions.     4. Stage IV (Severe): Multiple superficial and deep implants; large ovarian endometriomas; dense adhesions.

Therapeutic Strategies for Endometriosis: First-Line and Mild-to-Moderate Management

  • Mild to Moderate Pain Algorithm:     - Start with NSAIDs + Estrogen-Progestin Contraceptives.     - If successful, continue until pregnancy is desired or menopause.     - If unsuccessful, switch to a different COCP formulation while continuing NSAIDs.

  • First-Line Pharmacological Agents:     - NSAIDs: Ibuprofen (200−800 mg200-800\,mg TID) or Naproxen (200−550 mg200-550\,mg BID/TID).     - CHCs: Continuous use is often more effective than cyclic use to induce atrophy of endometrioma.     - Progestins: MPA, norethindrone, drospirenone, DMPA, or levonorgestrel IUD.

Advanced Pharmacological Management of Endometriosis: GnRH Modulators and Add-Back Therapy

  • GnRH Agonists (e.g., Leuprolide IM, Goserelin SC, Nafarelin nasal):     - Mechanism: Downregulates the pituitary, creating a "medical menopause"/pseudomenopausal state.     - Initial Flare: Leads to a temporary increase in FSH/LH, which may worsen pain initially (relief in 1 month1\,\text{month}).     - Side Effects: Hot flashes, night sweats, vaginal dryness, decreased Bone Mineral Density (BMD).

  • GnRH Antagonists:     - Elagolix (Orilissa):         - 150 mg150\,mg once daily (max 24 months24\,\text{months}).         - 200 mg200\,mg twice daily (max 6 months6\,\text{months} for dyspareunia).     - Relugolix Combination (Myfembree): Relugolix 40 mg40\,mg / Estradiol 1 mg1\,mg / Norethindrone 0.5 mg0.5\,mg once daily (max 24 months24\,\text{months}).     - Elagolix Combination (Oriahnn): Dosing for heavy bleeding with fibroids (max 24 months24\,\text{months}).     - Safety: Major concern for BMD loss (potentially irreversible).

  • Add-Back Therapy:     - Based on the "estrogen threshold hypothesis" to prevent hypoestrogenic side effects.     - Options: Progestin monotherapy, Estrogen-Progestin (e.g., Norethindrone 5 mg5\,mg + CEE 0.625 mg0.625\,mg), SERMs, or Bisphosphonates.     - Recommendation: Calcium supplementation (1000 mg1000\,mg daily in divided doses).

Second-Line Pharmacological and Surgical Interventions for Endometriosis

  • Aromatase Inhibitors: Letrozole or Anastrozole (usually combined with CHC or GnRH agonists).

  • Danazol: An androgenic agent that reduces the LH surge; side effects include weight gain, hirsutism, and a deepened voice.

  • Surgical Options:     - Indicated for large endometriomas or persistent symptoms.     - Laparoscopic uterosacral nerve ablation.     - Presacral neurectomy.     - Hysterectomy with Bilateral Salpingo-Oophorectomy (BSO).